deCODEme

deCODEme has blundered into the same “medicine that’s not medicine” fraudulent territory as Navigenics, but they do not make as good of a negative example as Navigenics does because deCODEme is not the DTC genomics leader. If deCODEme survives, it will follow the examples of others, so I propose no special effort to make them a negative example. It’s more important to focus the already diluted messages of the personalized medicine community than it is to be “fair.” However, I propose to hold deCODEme to the same standards as Navigenics if the challenge arises.